Cytogenetic Effects of Ranitidine on Stem Cell L-Asparaginase Treated Mice

[1] Bland KI, Csendes A. General surgery: principles and international practice. Springer 2008;2011.
[2] Dimarino AJ, Benjamin SB. Gastrointestinal disease: an endoscopic approach. Slack Incorporated 2002;1449.
[3] Thurmond R. Histamine in inflammation. Springer 2011;143.
[4] Lord RS, Bralle JA. Laboratory evaluations for integrative and functional medicine. Metametrix Institute 2008;662.
[5] Deva S, Jameson M. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer (Review). John Wiley and Sons, Ltd. 2012;32.
[6] Rajendra S, Mulcahy H, Patchett S, Kumar P. The effect of H2 antagonists on proliferation and apoptosis in human colorectal cancer cell lines. Dig Dis Sci 2004;49:1634–40.
[7] Hahm KB, Park IS, Kim HC, Lee KJ, Kim JH, Cho SW, et al.Comparison of antiproliferative effects of l-histamine-2 receptor antagonists, cimetidine, ranitidine, and famotidine, in gastric cancer cells. Int J Immunopharmacol. 1996;18: 393–9.
[8] Higuchi K, Watanabe T, Tominaga K, Shiba M, Nakagawa K, Uno H, et al. Effects of ranitidine on quality of gastric ulcer healing compared with famotidine: a randomized, controlled, multicenter trial. Int J Clin Pharmacol Res 2005;25:187–94.
[9] Rang HP, Ritter JM, Flower RJ, Henderson G. Rang and dales pharmacology, 8th edition. Elsevier Limited 2016:723.
[10] Nielsen HJ, Christensen IJ, Moesgaard F, Kehlet H. Ranitidine as adjuvant treatment in colorectal cancer. Br J Surg. 2002; 89:1416–22.
[11] Sartori S,Trevisani L, Nielsen I, Tassinari D, Panzini I, Abbasciano V. Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy induced gastro duodenal injury. J Clin Oncol 2000; 18:463–7.
[12] Degrassi F, Fiore M, Palitti F. Chromosomal aberrations and genomic instability induced by topoisomerase-targeted antitumour drugs. Curr Med Chem Anticancer Agents 2004;4:317–25.
[13] Attia SM. Mutagenicity of some topoisomerase II-interactive agents. Saudi Pharmaceutical Journal 2008;16:1–24.
[14] Becker F. Chemotherapy. Springer 2012;666.
[15] Savitri AN, Azmi W. Microbial l-asparaginase: a potential anti-tumor enzyme. IJBT 2003; 2:184-94.
[16] Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evolution of l-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol 2007; 61:208–21 .
[17] Patro KKR, Satpathy S, Gupta N. Evoluation of some fungi for l-asparaginase production. Indian J. of Fundamental and Applied Life Sciences 2011;1:219–21.
[18] El-Naggar NE, El-Ewasy SM, El-Shweihy NM. Microbial l-asparaginase as a potential therapeutic agent for the treatment of acute lymphoblastic leukemia: the pros and cons. International Journal of pharmacology 2014;10:182-99.
[19] Schroeder MA, Dipersio JF. Mobilization of hematopoietic stem and leukemia cells. J Leukoc Biol 2012;91:47–57.
[20] Chu E, Devita VT. Physicians’ cancer chemotherapy drug manual. Jones and Bartlett learning 2014:664.
[21] Hodgson BB, Kizior RJ. Saunders nursing drug handbook 2014. Elsevier Inc. 2014:1359.
[22] Raven R. Principles of surgical oncology. Springer 2012:510.
[23] Allen JW, Schuler CF, Mendes RW, Latt SA. Asimplified technique for in vivo analysis of sister chromatid exchange using 5- bromodeoxy uridine tablets. Cytogenet Cell Genet 1977;18:231–7.
[24] Schmid W. The micronucleus test. Mutat Res 1975;31:9–15.
[25] Umansky M, Yasui W, Hallak A, Brill S, Shapira I, Zand H, et al. Proton pump inhibitors reduce cell cycle abnormalities in barrett's esophagus. Oncogene 2001;20:7987–91.
[26] Warzecha Z, Dembiński A, Brzozowski T, Ceranowicz, P, Pajdo R, Niemiec J, et al. Gastroprotective effect of histamine and acid secretion
International Journal of Science and Engineering Investigations, Volume 5, Issue 56, September 2016 51
www.IJSEI.com Paper ID: 55616-08
ISSN: 2251-8843
on ammonia-induced gastric lesions in rats. Scand J Gastroenterol 2000;35:916–24.
[27] Francavilla A, Panella C, Polimeno L, DiLeo A, Makowka L, Barone M, et al. Effect of cimetidine, ranitidine, famotidine and omeprazole on hepatocyte proliferation in vitro. J Hepatol 1989;8:32–41.
[28] Biggar KK, Shawn S. Non-histone protein methylation as a regulator of cellular signaling and function. Nat Rev Mol Cell Biol 2015;16:5–17.
[29] Talwar GP. Textbook of biochemistry, biotechnology, allied and molecular medicine. PHI Learning Pvt. Ltd 2016:1632.
[30] Bourdet DL, Pollack GM, Thakker DR. Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells. Pharm Res 2006;23:1178–87.
[31] Paz-y-Miño C, Dávalos, MV, Sánchez ME, Arévalo M, Leone PE. Should gaps be included in chromosomal aberration analysis? evidence based on the comet assay. Mutat Res 2002;516:57–61.
[32] Shelke SP, Sarawade T, Baheti DG. New and simple spectroscopic method for ranitidine hydrochloride from bulk and formulation. IJPRBS 2012; 1:178–83.
[33] Brambilla G, Mattioli F, Martelli A. Genotoxic and carcinogenic effects of gastrointestinal drugs. Mutagenesis 2010;25:315–26.
[34] Maura A, Pino A, Robbiano L, Cajelli E, Finollo R, Cavanna M, et al. DNA damage induced by nitrosated ranitidine in cultured mammalian cells. Toxicol Lett. 1983;18:97–102.
[35] Sainani GS, Manika JS, Sainani RG. Oxidative stress: a key factor in pathogenesis of chronic diseases. Med Uptake 1997;1:1–4.
[36] Giri AK, Banerjee TS, Talukder G, Sharma A. Effects of dyes (indigo carmine, metanil yellow, fast green FCF) and nitrite in vivo on bone marrow chromosomes of mice. Cancer Lett 1986;30:315–20.
[37] BanerjeeTS, Giri AK. Effects of sorbic acid and sorbic acid-nitrite in vivo on bone marrow chromosomes of mice. Toxicol Lett 1986; 31:101–6.
[38] Bryce SM, Avlasevich SL, Bemis JC, Dertinge SD. Miniaturized flow cytometry-based CHO-K1 micronucleus assay discriminates aneugenic and clastogenic modes of action. Environ Mol Mutagen 2011;52:280–6.
[39] Shahidi M, Mozdarani H. Potent radioprotective effect of therapeutic doses of ranitidine and famotidine against gamma-rays induced micronuclei in vivo. Iran J Radiat Res 2003;1: 29–35.
[40] Long GQ, Zhen C, Long DQ. Effect of l-asparaginase, proliposome on toxicity in mice and experimental tumor. Journal-China Pharmaceutical University 2001;32:67–9 .
[41] He H,Ye J,Wang Y,Liu Q, ChungHS, KwonYM, et al. Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application. J Control Release 2014;176:123–32.
[42] Warrell RPJ, Arlin ZA, Gee TS, Chou TC, Roberts J, Young CW. Clinical Evaluation of succinylated acinetobacter glutaminase-asparaginase in adult leukemia. Cancer Treat Rep1982; 66:1479–85.
[43] Avramis VI. Is glutamine depletion needed in ALL disease?. Blood 2014;123:3532–3.
[44] Wagner A, Hempel G, Gumbinger HG, Jurgens H, Boos J. Pharmacokinetics of anticancer drugs in vitro; in drug resistance in leukemia and lymphoma III. Adv Exp Med Biol 1999;457:397–407.
[45] Story MD, Voehringer DW, Stephens LC, Meyn RE. L-asparaginase kills lymphoma cells by apoptosis. Cancer Chemother and Pharmacol 1993;32:129–33.
[46] Pui CH, Relling MV, Behm FG, Hancock ML, Boyett JM, Raimondi SC, et al. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 1995;9:1680–4.
[47] Warangkar SC, Khobragade CN. Purification, characterization, and effect of thiol compounds on activity of the Erwinia carotovora L-asparaginase. Enzyme Res 2009;2010:1–10.
[48] Ching TL, Jong J, Bast A. Structural characteristics of histamine H2 receptor antagonists that scavenge hypochlorous acid. Eur J Pharmacol 1994;268:89–93.
[49] Rani SA, Sundaram L, Vasantha, PB. A study on in vitro antioxidant and anticancer activity of l-asparaginase. Journal of Pharmacy Research 2012;5:1463–6.